Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready
InHouse Patent Counsel, LLC has 5 pending office actions in Biotechnology & Pharmaceuticals and 255 career applications. The current docket is small, while the application base supplies context for interpreting the reported outcomes.
The resolved allowance rate is 86.62%, and the average is 4.01 office actions per allowance. The rate indicates favorable allowance results in the resolved record, while the action average indicates that allowance commonly follows extended examination activity. Practitioners should account for the apparent outcome strength alongside the higher response burden reflected in the action metric.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 4 (80%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +30.0% |
| RAMIREZ, DELIA M | 1 | 65.1% | +56.3% |
| SAEED, KAMAL A | 1 | 83.9% | +9.8% |
| SAIDHA, TEKCHAND | 1 | 82.9% | +14.1% |
| FLINDERS, JEREMY C | 1 | 63.4% | +17.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705344 | MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE | SAEED, KAMAL A | — |
| 18477601 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | SAIDHA, TEKCHAND | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18173551 | BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS | FLINDERS, JEREMY C | 16d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18173551 | BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS | FLINDERS, JEREMY C | 16d overdue |
| 18950126 | TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES | STEADMAN, DAVID J | — |
| 18726717 | HEMOSTATIC COMPOSITION CONTAINING RECOMBINANT HUMAN CLOTTING FACTORS, AND METHOD OF PRODUCING | RAMIREZ, DELIA M | — |
| 18477601 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | SAIDHA, TEKCHAND | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Brandeis University | 1 |
| REGENTS OF THE UNIVERSITY OF MINNESOTA | 1 |
| Zywie, LLC | 1 |
| GLOBAL BIOENERGIES | 1 |
| U.S. Government | 1 |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1656 | 1 |
| 1626 | 1 |
| 1684 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18950126 | TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES | BRANDEIS UNIVERSITY | STEADMAN, DAVID J | 1656 | §112 | Non-Final OA | — | Pending | Nov 17, 2024 |
| 18726717 | HEMOSTATIC COMPOSITION CONTAINING RECOMBINANT HUMAN CLOTTING FACTORS, AND METHOD OF PRODUCING | Regents Of The University Of Minnesota | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18705344 | MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE | Zywie, LLC | SAEED, KAMAL A | 1626 | §112 | Final Rejection | — | Pending | Apr 26, 2024 |
| 18477601 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | Global Bioenergies | SAIDHA, TEKCHAND | 1652 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18173551 | BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS | The United States Government (Department of the Army) | FLINDERS, JEREMY C | 1684 | §102§112Other | Non-Final OA | 16d overdue | Pending | Feb 23, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial86.6% of resolved applications prosecuted by Inhouse Patent Counsel, LLC were allowed, across 255 applications in USPTO records.
4.01 office actions per allowed application on average.
5 pending office actions as of November 2026, for 5 clients, before 5 examiners in 4 art units.